Find clinical trials for Lymphoma in Birmingham, AL

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Lymphoma
Non-Hodgkin Lymphoma
Lymphoid Leukemia
Diffuse Large B-Cell Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
B-Cell Chronic Lymphocytic Leukemia

Lymphoma trials near Birmingham, AL, USA:

Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma

dose of BGB-11417 monotherapy for relapsed or refractory mantle cell lymphoma. Part 2 evaluates efficacy of BGB-11417 monotherapy at the rec...

Mantle Cell Lymphoma
Relapsed Mantle Cell Lymphoma
Drug: BGB-11417

Phase 1, Phase 2


Birmingham, Alabama, United States and 73 other locations

A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas...

EBV Associated Lymphoma
EBV Related Non-Hodgkin's Lymphoma
Drug: Nanatinostat in combination with valganciclovir

Phase 2

Viracta Therapeutics

Birmingham, Alabama, United States and 93 other locations

treatment of advanced classical Hodgkin lymphoma(HL)...

Active, not recruiting
Hodgkin Lymphoma
Drug: brentuximab vedotin
Drug: bleomycin

Phase 3


Birmingham, Alabama, United States and 215 other locations

to assess the efficacy and safety of golcadomide in combination with rituximab in participants with newly diagnosed advanced stage Follicular Lymphoma...

Begins enrollment this month
Lymphoma, Follicular
Drug: Golcadomide
Drug: Doxorubicin

Phase 2


Birmingham, Alabama, United States and 64 other locations

pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia or cytotoxic lymphomas...

Other CD8+/NK Cell Driven Lymphoma Not Listed Above
Subcutaneous Panniculitis-Like T-Cell Lymphoma
Drug: DR-01

Phase 1, Phase 2

Dren Bio

Birmingham, Alabama, United States and 31 other locations

of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after lymphodepletion consisting of cyclophosphamide and fludarabin...

Refractory B-Cell Non-Hodgkin Lymphoma
B Cell Lymphoma
Genetic: CB-010
Drug: Cyclophosphamide

Phase 1

Caribou Biosciences

Birmingham, Alabama, United States and 29 other locations

trial will enroll patients with relapsed/refractory non-Hodgkin lymphoma of B-cell origin and is conducted in two phases. The primary object...

Non Hodgkin Lymphoma
Drug: Rituximab
Drug: Cyclophosphamide

Phase 1, Phase 2

Artiva Biotherapeutics

Birmingham, Alabama, United States and 20 other locations

This is an open label, multi-cohort, and multi-center phase II study, which evaluates the clinical activity and safety of IPH4102 in Sezary Syndrome...

Active, not recruiting
Lymphoma, T-Cell
Lymphoma, T-Cell, Cutaneous
Biological: IPH4102

Phase 2

Innate Pharma

Birmingham, Alabama, United States and 52 other locations

with other therapies, when treating subjects with B-cell non-Hodgkin Lymphoma (B-NHL). The aim of the first part of the trial is to identify...

Follicular Lymphoma
Diffuse Large B-Cell Lymphoma
Drug: rituximab and lenalidomide
Drug: gemcitabine and oxaliplatin

Phase 1, Phase 2


Birmingham, Alabama, United States and 63 other locations

is a Phase 1, open-label, dose escalation and dose expansion study of CLN-978 in patients with Relapse/Refractory (R/R) B-cell Non-Hodgkin Lymphoma...

Active, not recruiting
NHL, Relapsed, Adult
Drug: CLN-978

Phase 1

Cullinan Therapeutics Inc.

Birmingham, Alabama, United States and 5 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems